Indian biotechnology company Bharat Biotech on Sunday issued a clarification over comment of The supply of the Covid-19 vaccine is reported by the World Health Organization (WHO) through the United Nations procurement agencies news ANI Agency. The Hyderabad-based company said in Statement that “there is no effect on efficacy and safety of The COVID-19 vaccine COVAXIN”.
“to millions who I have received COVAXIN, vaccine certificates issued are still valid as there is no effect on efficacy and safety of the vaccine “.
On Saturday, the United Nations health agency suspended the supply of Covaxin is under the Covax facility, attributing it to the shortcomings in manufacturing practices.
The World Health Organization (WHO) today confirms the suspension of supply of Covaxin produced by Bharat (Biotech), through United Nations procurement agencies and recommended by countries that received the vaccine to take appropriate action,” the UN agency said in a permit.
comment was announced After the World Health Organization post-Emergency use The inspection of the list was carried out from 14 to 22 March. Inspection highlighted need To make process and facility upgrades to address recently identified good manufacturing practice (GMP) shortcomings.
Bharat Biotech says it’s slowing down down output of Covaccin for hanging attachment maintenanceprocess and facility improvement activities.
“As all existing facilities have been redirected for other purposes for Industry of cofaxine, with Continuous production during past yearto meet public health emergency of COVID-19, these upgrades were due. Certain highly developed equipment that was required To reinforce the rigor of the process was not available during the COVID-19 pandemic. Quality must be emphasized of COVAXIN has never been compromised in the time is added.
K resultThere will be a break of the supply of Cofaxine.
The company insisted that it was “working hard to bring more improvements and upgrades to ensure that production of COVAXIN continues to face the constant increase global regulatory requirements. ”
“where patient safety is the primary consideration for any new Vaccine, there can be no concessions in operational meeting excellence Objectives ” added.
World Health Organization also said that risk Evaluation so far does not indicate a change in The risk- interest rate, with There are no issues related to safety and efficacy of Vaccine.
‘data available To the World Health Organization, indicate that the vaccine is effective and not safety Anxiety exists. to continue of vaccination with alternative sources of COVID19 Vaccines countries should Refer to the relevant SAGE recommendation,” the statement read.
(with ANI input)
.
